Concepta successfully launches 'myLotus' in the UK

Healthcare company Concepta told the market of the successful launch in the UK of its ‘myLotus’ product for women's fertility on Monday.

The AIM-traded firm explained that myLotus allowed women to self-test to identify their optimal fertile days, thereby improving their chances of naturally getting pregnant.

It said myLotus enabled women to monitor their fertile phase as part of their menstrual cycle, and was the only home test to 'quantitatively' measure personalised hormone levels and the 'rate-of-change' of those levels preceding ovulation, to help aid a natural conception.

Users measured, recorded and tracked their hormone levels, and followed their fertility journey in an accompanying free downloadable app.

Concepta said that while awareness, profile and sales of the myLotus device were commencing, feedback from early users and fertility bloggers had still been “very positive”.

Discussions had also commenced with what the company described as 'key opinion leaders' to advise on the wider use of myLotus, especially for women who wished to monitor their hormonal levels, and for those who had previously struggled to conceive naturally, enabling an alternative for couples prior to considering more costly in vitro fertilisation (IVF) treatment.

In addition to the growing myLotus digital UK presence, the company said it was preparing plans for the roll-out of myLotus across Europe under its CE-mark approval.

Commercial discussions had also begun with retail providers, to make myLotus more broadly available across the UK.

“Although marketing and communications around myLotus® are just beginning, feedback from the early users has been exceptional,” said Concepta chairman Matthew Walls.

“We will be raising awareness of the value of the myLotus device and its window on fertility over the coming months via an increased online presence, key opinion leaders and marketing of our initial fertility case studies.”